Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1992 Jan;119(1):41–45. doi: 10.1007/BF01209486

Toxicity associated with the formation and clearance of immune complexes between antitumour monoclonal antibodies and syngeneic anti-idiotypic antibodies in mice

M V Pimm 1,✉, S J Gribben 1
PMCID: PMC12201422  PMID: 1400564

Abstract

We have previously shown that Balb/c mice immunised against syngeneic monoclonal antibodies (mAbs), so that they have anti-idiotypic responses against those mAbs, will clear the mAbs from the circulation as a result of immune complex formation. We report here that with three separate mAbs, this clearance of complexes can result in toxicity to the animals. This was particularly severe with one mAb (NCRC-2), in some cases leading to death. It was not seen with Fab/c or Fab fragments of NCRC-2. This toxic response could be passively transferred with serum, indicating that it was due to formation of immune complexes or to their subsequent clearance. Treatment of mice with cobra venom factor, to reduce complement levels, reduced clearance of complexes but had no effect on toxicity. The anti-histamine pyrilamine did not reduce toxicity. The anti-histamine pyrilamine did not reduce toxicity. This is one of only a few situations in which an anti-(mouse antibody)response has been reported to be potentially dangerous, and is particularly remarkable since it occurs as a result of such a limited anti-antibody response.

Key words: Monoclonal antibodies, Anti-idiotypic responses, Immune complexes, Toxicity

Abbreviations

mAb

monoclonal antibody

CEA

carcinoembryonic antigen

PBS

phosphate-buffered saline, pH 7.2

References

  1. Azuma J, Kurimoto T, Tsuji S, Mochizuki N, Funjinaga S, Matsumoto Y, Masuho Y (1991) Phase I study on human monoclonal antibody against cytomegalovirus: pharmacokinetics and immunogenicity. J Immunother 10:278–285 [DOI] [PubMed] [Google Scholar]
  2. Brown PS, Parenteau GL, Dirbas FM, Garsia RJ, Goldman CK, Bukowski MA, Junghans RP, Queen C, Hakimi J, Benjamin WR, Clark RE, Waldman TA (1991) Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci USA 88:2663–2667 [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Demignot S, Pimm MV, Baldwin RW (1990) Comparison of biodistribution of 791T/36 monoclonal antibody and its Fab/c fragment in Balb/c mice and nude mice bearing human tumour xenografts. Cancer Res 50:2936–2942 [PubMed] [Google Scholar]
  4. Dillman R (1990) Human antimouse and antiglobulin response to monoclonal antibodies. Antibody Immunoconj Radiopharmacol 3:1–15 [Google Scholar]
  5. Embleton MJ, Gunn B, Byers VS, Baldwin RW (1981) Antitumour reactions of monoclonal antibody against a human osteogenic-sarcoma cell line. Br J Cancer 43:582–587 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fraker PJ, Speck JC (1978) Protein and cell membrane iodination with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril. Biochem Biophys Res Commun 80:849–857 [DOI] [PubMed] [Google Scholar]
  7. Furness PN, Turner DR (1988) Chronic serum sickness glomerulonephritis: removal of glomerular antigen and electron-dense deposits is largely dependent on plasma complement. Clin Exp Immunol 74:126–130 [PMC free article] [PubMed] [Google Scholar]
  8. Hird V, Verhoeyen M, Badley RA, Price D, Snook D, Kosmas C, Gooden C, Bamias A, Meares C, Lavender JP, Epenetos AA (1991) Tumour localization with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer 64:911–914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kaminski MS, Kitamura K, Maloney DG, Levy R (1987) Idiotype vaccination against murine B cell lymphoma. Inhibition of tumour immunity by free idiotype protein. J Immunol 138:1289–1296 [PubMed] [Google Scholar]
  10. Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, Colcher D, Schlom J, Shochat D, LoBuglio AF (1991) Pharmacokinetics and immune response of131I-chimeric mouse/human B72.3 (human γ4) monoclonal antibody in humans. Cancer Res 51:5461–5466 [PubMed] [Google Scholar]
  11. Meredith RF, LoBuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Wheeler RH, Saleh MN, Rogers KJ, Polansky A, Salter MM, Khazaeli MB (1991) Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,K 17-1A monoclonal antibody. J Nucl Med 32:1162–1168 [PubMed] [Google Scholar]
  12. Morgan BP (1990) Complement-clinical aspects and relevance to disease. Academic Press, London [Google Scholar]
  13. Neuberger MS, Rajewsky K (1981) Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol 11:1012–1016 [DOI] [PubMed] [Google Scholar]
  14. Pimm MV, Baldwin RW (1990) Syngeneic anti-idiotypic antibody prevents localization of a murine monoclonal antibody in human tumour xenografts. Eur J Cancer 26:567–568 [DOI] [PubMed] [Google Scholar]
  15. Pimm MV, Perkins AC, Durrant LG, Baldwin RW (1988) A rat model for imaging the effect of anti-mouse antibody responses on the biodistribution of radiolabelled mouse monoclonal antibodies. Eur J Nucl Med 14:507–511 [DOI] [PubMed] [Google Scholar]
  16. Pimm MV, Durrant LG, Baldwin RW (1989) The influence of syngeneic anti-idiotypic antibody on the biodistribution of an antitumour monoclonal antibody in Balb/c mice. Int J Cancer 43:147–151 [DOI] [PubMed] [Google Scholar]
  17. Price MR, Edwards S, Jacobs E, Pawluczyk IZA, Byers VS, Baldwin RW (1987) Mapping of monoclonal antibody-defined epitopes associated with carcinoembryonic antigen, CEA. Cancer Immunol Immunother 25:10–15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Price MR, Sekowski M, Tendler SJB (1991) Purification of anti-epithelial mucin monoclonal antibodies by epitope affinity chromatography. J Immunol Methods 139:83–90 [DOI] [PubMed] [Google Scholar]
  19. Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, Larson SM, Smith JW, Clark JW, Dailey V, Vecchio SD, Shuke N, Pinsky CM, Urba WJ, Haspel M, Perentesis P, Paris B, Longo DL, Hanna MG (1990) Toxicity, immunogenicity and tumour radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol 8:476–490 [DOI] [PubMed] [Google Scholar]
  20. Van Kroonenburgh MJPG, Pauwels EKJ (1988) Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun 9:919–930 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES